Author

Taeyoun Jo

Observed name: T Jo

Institution: Sungkyunkwan University

Observed institutions: Pfizer (United States), Sungkyunkwan University

OpenAlex ID: A5034928199

Analysis of Phase I Clinical Trial Design of Anti-Cancer Agents

2025 · Juhee Cho, Haesook Bok, et al. · Therapeutic Innovation & Regulatory Science · 1

Loneliness and health-related quality of life by chronic disease: a nationally representative survey

2026 · Jihye Heo, Hyeonjin Cho, et al. · International Journal of Epidemiology

A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients With Locally Advanced or Metastatic Cancers

2021 · A Diab, O Hamid, et al. · immuneACCESS

Works count: 3

Citation count: 1

H-index: 1

I10-index: